Focused On-demand Library for Sushi repeat-containing protein SRPX2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O60687

UPID:

SRPX2_HUMAN

Alternative names:

Sushi-repeat protein upregulated in leukemia

Alternative UPACC:

O60687; B3KQT3; Q8WW85

Background:

The Sushi repeat-containing protein SRPX2, also known as Sushi-repeat protein upregulated in leukemia, plays a pivotal role in various biological processes. It acts as a ligand for the urokinase plasminogen activator surface receptor, contributing to angiogenesis through endothelial cell migration and vascular network formation. SRPX2 is also involved in cellular migration, adhesion, and increases the phosphorylation levels of FAK. Furthermore, it interacts with HGF to enhance mitogenic activity and promotes synapse formation, indicating a significant role in the perisylvian region crucial for language and cognitive development.

Therapeutic significance:

SRPX2's involvement in Rolandic epilepsy, impaired intellectual development, and speech dyspraxia, X-linked, underscores its therapeutic potential. Understanding the role of SRPX2 could open doors to potential therapeutic strategies for these conditions, highlighting the importance of targeted research in uncovering novel treatment avenues.